More specifically, we found that hepatic Smo activity is greater in obese patients with healthy-appearing livers than in comparably obese patients with NAFLD, and demonstrated that Smo declines in a stepwise fashion as the severity of liver injury and fibrosis increase. Here, SMO is linked to metabolic dysfunction-associated steatotic liver disease.